Contact Information: For More Information, Contact: James E. Fickenscher CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 William Q. Sargent, Jr. V.P., IR Auxilium Pharmaceuticals, Inc. (484) 321-5900
Auxilium Pharmaceuticals to Present at the UBS Global Life Sciences Conference
| Source: Auxilium Pharmaceuticals, Inc.
MALVERN, PA--(Marketwire - September 8, 2009) - Auxilium Pharmaceuticals, Inc. (NASDAQ : AUXL )
today announced that executive management will participate in the UBS
Global Life Sciences Conference to be held September 21 - 23, 2009 at the
Grand Hyatt in New York City. Mr. Armando Anido, Chief Executive Officer
and President, is scheduled to present an overview of the Company and its
product pipeline at 10:30 a.m. EDT on Monday, September 21, 2009.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for ninety days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets Testim®
1%, a topical testosterone gel, for the treatment of hypogonadism through
its approximately 190-person sales and marketing team. Auxilium has five
projects in clinical development. XIAFLEX™ (collagenase clostridium
histolyticum), formerly referred to as AA4500, has completed phase III
clinical trials for the treatment of Dupuytren's disease, and the biologics
license application is under review at the FDA for the treatment of
Dupuytren's disease. XIAFLEX is in phase IIb of development for the
treatment of Peyronie's disease and is in phase II of development for
treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's
transmucosal film product candidate for the treatment of overactive bladder
(AA4010) and its fentanyl pain product using its transmucosal delivery
system are in phase I of development. The Company is currently seeking a
partner to further develop these product candidates. Auxilium has rights
to additional pain products and products for hormone replacement and
urologic disease using its transmucosal film delivery system. Auxilium
also has options to all indications using XIAFLEX for non-topical
formulations. For additional information, visit http://www.auxilium.com.
Safe Harbor Statement
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the UBS Global Life
Sciences Conference, and products in development for the treatment of
Dupuytren's contracture, Peyronie's disease and Frozen Shoulder Syndrome
and for pain, hormone replacement and urologic disease. All statements
other than statements of historical facts contained in this release,
including but not limited to, statements regarding future expectations,
plans and prospects for the Company, statements regarding forward-looking
financial information and other statements containing the words "believe,"
"may," "could," "will," "estimate," "continue," "anticipate," "intend,"
"should," "plan," "expect," and similar expressions, as they relate to the
Company, constitute forward-looking statements. Actual results may differ
materially from those reflected in these forward-looking statements due to
various factors, including further evaluation of clinical data, results of
clinical trials, decisions by regulatory authorities as to whether and when
to approve drug applications, and general financial, economic, regulatory
and political conditions affecting the biotechnology and pharmaceutical
industries and those discussed in the Company's Annual Report on Form 10-K
for the year ended December 31, 2008 and the Company's Quarterly Report on
Form 10-Q for the period ended June 30, 2009 under the heading "Risk
Factors," which are on file with the Securities and Exchange Commission
(the "SEC") and may be accessed electronically by means of the SEC's home
page on the Internet at http://www.sec.gov or by means of Auxilium's home
page on the Internet at http://www.Auxilium.com under the heading "Investor
Relations -- SEC Filings." There may be additional risks that Auxilium does
not presently know or that Auxilium currently believes are immaterial which
could also cause actual results to differ from those contained in the
forward-looking statements. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.